Allspring Global Investments’s Contineum Therapeutics CTNM Stock Holding History

Allspring Global Investments’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$322K	Buy	+19,653	New	+$258K	﹤0.01%	1558

Other funds holding CTNM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SAM

Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RTM

Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Allspring Global Investments's CTNM Position: Q2 2026 in Review

Allspring Global Investments opened a new position in Contineum Therapeutics (CTNM) in Q2 2026: 19,653 shares worth $322K. The stake represents ﹤0.01% of the portfolio and ranks #1558 among its holdings.

69 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

Allspring Global Investments held 19,653 shares of Contineum Therapeutics worth $322K as of Q2 2026.
Contineum Therapeutics was a new Allspring Global Investments position in Q2 2026.
Contineum Therapeutics made up ﹤0.01% of Allspring Global Investments's portfolio in Q2 2026, its #1558 holding.
69 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Allspring Global Investments's 13F filing for Q2 2026, filed 13 Aug 2026.